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Edited by Jesus AvilaAbstract Mice lacking tob2, a member of the antiproliferative
family genes, had decreased bone mass, and the number of osteo-
clasts diﬀerentiated from bone marrow cells was increased. Over-
expression of Tob2 in stromal cells repressed vitamin D3-induced
osteoclasts formation. Furthermore, expression of RANKL
mRNA in stromal cells was increased in the absence of Tob2
and decreased in the presence of Tob2. Tob2 interacted with vita-
min D3 receptor (VDR), which suggests its involvement in vita-
min D3 receptor-mediated regulation of transcription. Because
VDR regulates RANKL expression, our data suggest that
Tob2 negatively regulates formation of osteoclasts by suppress-
ing RANKL expression through its interaction with VDR.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Vitamin D31. Introduction
Tob2 is a member of Tob/BTG family of antiproliferative
proteins, and exogenous expression of Tob family proteins sup-
presses growth of NIH3T3 cells by inhibiting G1 progression of
the cell cycle [1]. Tob2, like other Tob family members, interacts
with Caf1/Cnot7 [2], which is a component of the CCR4-NOT
protein complex [3]. Caf1/Cnot7 interacts with nuclear recep-
tors ERa and RXRb [4,5]. Moreover, the CCR4-NOT complex
participates in control of expression of speciﬁc sets of genes [3].
Both BTG1 and BTG2 associate with HoxB9 and enhance
HoxB9-mediated transcription [6]. Tob associates with the
Smads transcription complex and aﬀects Smad-mediated gene
expression [7,8]. These ﬁndings suggest that Tob family proteins
are involved in transcriptional regulation. Because Tob family
members do not have DNA-binding domains, they are thoughtAbbreviations: RANKL, receptor activator of NF-jB ligand; FBS,
fetal bovine serum; RT-PCR, reverse-transcriptase polymerase chain
reaction; MEFs, mouse embryonic ﬁbroblasts; TRAP, tartrate-resis-
tant acid phosphatase; GST, glutathione-s-transferase
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doi:10.1016/j.febslet.2008.03.012to function as either co-activators or co-repressors in conjunc-
tion with various transcription factors.
We reported previously that Tob is involved in bone meta-
bolism and that tob-deﬁcient mice develop an osteopetrotic
phenotype [7,9]. The high level of bone mass seen in adult
tob-deﬁcient mice was due to an increase in bone formation
by osteoblasts with little alteration in bone resorption. We re-
port here that, in contrast to tob-deﬁcient mice, adult mice
lacking tob2 show low levels of bone mass due to an increase
in the number of osteoclasts.2. Materials and methods
2.1. Generation of tob2/ mice
An 8-kbp and a 1.5-kbp fragment ﬂanking the 5 0 and 3 0 sites, respec-
tively, of an exon of the tob2 gene [10] were ligated to the 5 0 end of the
nlsLacZ and the 3 0 end of the NeoR genes of pBluescript SK+ (Strata-
gene), respectively. The Diphtheria toxin A (DTA) gene was ligated to
the 3 0 end of the targeting cassette. The plasmid was linearized and elec-
troporated into J1 embryonic stem (ES) cells [11]. After selecting G418-
resistantES clones, tob2-targeted cloneswere identiﬁedbySouthernblot
hybridization using probe 1 (Fig. 1A). The cells carrying the targeted al-
lele were injected into C57BL/6J blastocysts. Homozygosity of the tob2
knockout allele was conﬁrmed by Southern blotting and immunoblot-
ting as described [5]. Anti-Tob2 antibodies used were described [2].2.2. Microfocus-X-ray computed tomography (lCT) analysis of bone
and bone histomorphometry
To measure bone volume, femora of 9-month-old male mice were
subjected to lCT analysis as described previously [9]. For bone histo-
morphometry, femora of 9-month-old male mice were analyzed as de-
scribed previously [7].2.3. Retroviral transduction
Mouse tob2 coding region (mtob2) and ﬂag-tagged human tob2
cDNA (htob2F) were inserted between the LTR sequences of pMX-
puro expression plasmid, and the resulting plasmids were transfected
into Plat E cells for retrovirus production as described [12].2.4. Cell culture
COS-7 monkey kidney-derived cells and ST2 mouse bone marrow-
derived stromal cells were cultured in DMEM and aMEM (Gibco) sup-
plemented with 10% fetal bovine serum (FBS) (Sigma), respectively.
For real-time reverse-transcriptase polymerase chain reaction (RT-
PCR), ST2 was cultured in phenol red-free aMEM supplemented with
10% charcoal-stripped FBS, and treated with indicated concentrationsblished by Elsevier B.V. All rights reserved.
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Fig. 1. Targeted disruption of the tob2 gene. (A) Schematic illustration of tob2 targeting vector. The coding region is shown as a closed box. Arrows
on each box show the direction of each gene cassette. The SphI-digested DNA fragment detected by probe1 is shown as two-headed arrows. S, SphI;
N, NcoI. (B) Tail DNAs from F1 progeny of two heterozygote intercrosses were digested with SphI and subjected to Southern blot hybridization
with probe 1. Sizes of the DNA fragments are indicated on the left. (C) Protein lysates prepared from primary embryonic ﬁbroblasts infected with or
without mtob2 expression viruses were analyzed by immunoblotting with the anti-Tob2 antibodies (top panel) and anti-a-tubulin antibodies (bottom
panel).
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Bone marrow cells were collected from femur and cultured in aMEM
supplemented with 10% FBS. The cultured medium was changed every
2 days for one week. Mouse embryonic ﬁbroblasts (MEFs) were ob-
tained from 14.5-day-old embryos and cultured in DMEM containing
10% FBS and 50 lM b-mercaptoethanol.
2.5. In vitro osteoclast-like cell formation
Mouse splenocytes or bone marrow cells (106/well) were cultured for
7 days in the presence of 10 ng/ml M-CSF and 30 or 100 ng/ml soluble
form of receptor activator of NF-jB ligand (sRANKL) or co-cultured
with ST2 cells (2 · 104/well) in the presence of 10 nM 1,25-(OH)2D3
and 1 lM prostaglandin E2 in 24 well plates. Mouse bone marrow cells
(106/well) were cultured for 7 days in the presence of 10 nM 1,25-
(OH)2D3 and 1 lM prostaglandin E2 in 24-well plates. The cells were
then stained for tartrate-resistant acid phosphatase (TRAP), and the
number of osteoclast-like TRAP-positive multinucleated (>3 nuclei)
cells was counted.
2.6. Real-time RT-PCR
Total RNAs were reverse transcribed by a SuperScriptII First-
Strand Synthesis System (Invitrogen) using oligo(dT). Real-time
RT-PCR was performed as described [13]. Primer sequences were as
follows: Tob2 forward 5
0
-GCATTCATGCCTGTGAGTGTGTGGC
TTGC-3
0
, Tob2 reverse 5
0
-GGGTTTCTCGGGCTTAGCCTCGTGT
CA-3 0, RANKL forward 5 0-ATTTGCACACCTCACCATCAA-30,
RANKL reverse 5 0- TAGAGATCTTGGCCCAGCCTC-3 0, HPRT
forward 5 0-GTAATGATCAGTCAACGGGGGAC-3 0, and HPRT re-
verse 5 0-CCAGCAAGCTTGCAACCTTAACCA-3 0.2.7. Glutathione-s-transferase (GST) pull-down
Cells were lysed with TNE buﬀer 36 h after transfection and sub-
jected to aﬃnity pull-down assay as described [5]. Anti-c-Myc and
anti-GST antibodies were from Santa Cruz Biotechnology.3. Results
3.1. Bone mass is decreased in tob2/ mice
The tob2-targeting vector (Fig. 1A) was introduced into J1
ES cells to obtain homologous recombinants. Among 96 inde-
pendently selected ES cell clones, two tob2-targeted clones were
injected into C57BL/6 recipient blastocysts, and male chimeras
were crossed to C57BL/6 females. Germ-line transmission of
the ES cell genome was monitored by inspection for agouti coat
color and by Southern blot hybridization. tob2/ mice were
obtained by crossing tob2+/ mice (Fig. 1B and C). tob2/
mice were alive at birth and were obtained at predicted Mende-
lian frequencies. No apparent phenotypic abnormalities were
observed within a year after birth except that the bone mass
was decreased compared with that of tob2+/+ littermates. lCT
analysis revealed that the bone mass of tob2/ mice was
approximately 62% that of tob2+/+ littermates at 9 months of
age (Fig. 2A and B). Further histomorphometric analysis
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Fig. 2. tob2 deﬁciency reduces bone volume. (A) lCT analysis of femora of tob2+/+ or tob2/ mice. (B) lCT-based quantiﬁcation of the bone
volume (BV)/total tissue volume (TV) within the areas indicated by the rectangles in (A). (C–H) Histomorphometric analysis of markers of tob2+/+ or
tob2/ mice. (C) Bone to tissue ratio (in volume) (BV/TV) reﬂects bone mass. (D, E) Osteoblast surface (ObS/BS) and osteoclast surface (OcS/BS)
indicate the portion of bone surface covered by osteoblasts and osteoclasts, respectively. (F) Eroded surface (ES/BS) represents the function of
osteoclasts. Bars represent means ± S.D. Asterisks indicate a statistically signiﬁcant diﬀerence between tob2+/+ and tob2/ mice (*P < 0.01,
**P < 0.025, ***P < 0.05 by Students t test, n = 3, tob2+/+; 4, tob2/ for A and B, n = 3 each for D–F).
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histomorphometric index of trabecular bone mass, was de-
creased in tob2/ mice as compared with that of wild-type lit-
termates (Fig. 2C). To determine whether the increase in
trabecular bone mass was due to altered bone remodeling, we
examined three markers: osteoblast surface (ObS/BS, propor-
tion of bone surface covered with osteoblasts), osteoclasts sur-
face (OcS/BS, proportion of bone surface covered with
osteoclasts) and eroded surface (ES/BS, proporpositive of bone
surface eroded by osteoclasts) in tob2+/+ and tob2/ mice. The
osteoblast surface in tob2/mice has no statistically signiﬁcant
diﬀerence with that in tob2+/+ mice (Fig. 2D), suggesting that
decreased bone mass in tob2/ mice was not due to reduced
osteoblast numbers. In contrast, the osteoclast surface and
eroded surface, which are reliable indicators of osteoclast pop-ulation and function, were increased signiﬁcantly in tob2/
mice and was 317% and 199% greater than that of tob2+/+,
respectively (Fig. 2E and F). Thus, we concluded that the
decreased bone mass in tob2/ mice was due to increased
osteoclast numbers and accelation of the bone resorption
rate.
3.2. Tob2 expression in bone forming and bone modifying cells
Tob2 is ubiquitously expressed throughout most of tissues
[2,10]. The ubiquitous expression was conﬁrmed by LacZ
staining using tissues that obtained from tob2+/ mice (data
not shown). To address whether Tob2 is expressed in cells re-
lated to bone formation, we examined expression of Tob2 in
stromal cells and osteoclasts. Tob2 was expressed in both stro-
mal cells derived from bone marrow and stromal cell line ST-2,
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Fig. 3. Eﬀect of Tob2 on osteoclast/osteoblast formation. (A) Stromal cells were collected from wild type mice bone marrow and stimulated with or
without 10 nM 1,25-(OH)2D3 and 1 lM prostaglandin E2. Total RNA was collected 48 h after stimulation. ST-2 cells were stimulated with 10 nM
1,25-(OH)2D3, 10 nM dexamethasone (DEX) and 1 lM prostaglandin E2 (PGE2), then total RNA was collected at indicated time points and
subjected to semi-quantitative real-time RT-PCR analysis to examine Tob2 expression. Relative expression levels that compared with HPRT are
shown. (B) Bone marrow cells were cultured with 10 ng/ml M-CSF or 10 ng/ml M-CSF and 100 ng/ml sRANKL. Total RNA was collected 7 days
after stimulation and subjected to semi-quantitative real-time RT-PCR analysis as in (A). Relative expression levels that compared with HPRT are
shown. (C) Tob2 expression reported by LacZ staining is shown. Cells are cultured as in (B) and stained with X-gal. All the cells including stromal
cells, osteoclast precursors (in ﬁeld of M-CSF culture) and osteoclasts (in ﬁeld of M-CSF+sRANKL culture; indicated with arrows) stained with X-
gal. (D) In vitro osteoblast-colony-formation assay with tob2+/+ or tob2/ bone marrow cells. (E) In vitro osteoclast-formation assay with tob2+/+ or
tob2/ bone marrow cells cultured with 10 nM 1,25-(OH)2D3 and 1 lM prostaglandin E2. (F) In vitro osteoclast-formation assay with tob2
+/+ or
tob2/ splenocytes cultured with 10 ng/ml M-CSF and 30 ng/ml sRANKL. (G) In vitro osteoclast-formation assay performed by co-culturing
splenocytes with ST-2 cells infected with mock or htob2F expression viruses in the presence of 10 nM 1,25-(OH)2D3 and 1 lM prostaglandin E2. Bars
represent means ± S.D. * p < 0.05, by Students t test, n = 3.
1316 R. Ajima et al. / FEBS Letters 582 (2008) 1313–1318
R. Ajima et al. / FEBS Letters 582 (2008) 1313–1318 1317and the expression level was slightly increased when the cells
stimulated with 1,25(OH)2D3 (Fig. 3A). Furthermore, consis-
tent with previous report [7], Tob2 expression was higher in
osteoclasts that were diﬀerentiated from bone marrow cells
upon M-CSF and sRANKL stimulation than in bone marrow
cells cultured in the presence of M-CSF which contains stro-
mal cells and osteoclast precursor cells (Fig. 3B). LacZ staining
of each cell population conﬁrmed Tob2 expression in both cell
types (Fig. 3C).
3.3. Tob2 decreases osteoclast diﬀerentiation
To examine regulation of osteoblasts or osteoclasts forma-
tion of tob2/mice, we cultured bone marrow cells from femur
and performed diﬀerentiation assays. The number of osteoblast
colonies diﬀerentiated from bone marrow cells of tob2+/+ and
tob2/ mice did not diﬀer signiﬁcantly (Fig. 3D). In contrast,
the number of osteoclasts diﬀerentiated from bone marrow cells
of tob2/ mice upon stimulation with osteotropic factor,
1,25(OH)2D3, was signiﬁcantly higher than that from tob2
+/+
mice (Fig. 3E). These results are consistent with the results
shown in vivo (Fig. 2).
RANKL produced by stromal cells activates RANK ex-
pressed on the surface of osteoclast precursors, resulting in dif-
ferentiation, formation, fusion and survival of osteoclasts. To
investigate the ability of osteoclast precursors in tob2/ mice
to diﬀerentiate into mature osteoclasts, we cultured spleno-
cytes containing osteoclast precursors from tob2+/+ and
tob2/ mice with sRANKL. We found that the rates of osteo-
clast formation from osteoclast precursors did not diﬀer signif-
icantly between tob2/ and tob2+/+ mice (Fig. 3F). These data
suggest that RANK expression is not altered in the absence of
Tob2. We then examined the eﬀect of Tob2 on the function of
stromal cells. We found that diﬀerentiation of splenocytes into
osteoclasts was clearly suppressed when co-cultured with
Tob2-expressing ST2 cells (Fig. 3G). On the basis of these
data, we concluded that Tob2 negatively regulates stromal
cell-induced diﬀerentiation of osteoclasts.A
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Fig. 4. Eﬀect of Tob2 on RANKL expression. (A) Stromal cells were collecte
10 nM 1,25-(OH)2D3 and 1 lM prostaglandin E2. Total RNA was collected
PCR analysis. Expression of RANKL was normalized to that of HPRT. B
analysis of RANKL expression in ST2 stromal cell lines infected with mock
1,25-(OH)2D3, 10 nM dexamethasone (DEX) and 1 lM prostaglandin E2 (P
expression virus also showed similar results (data not shown).3.4. Tob2 regulates RANKL expression in stromal cells
RANKL activates mature osteoclasts, inducing actin ring
formation and bone resorption. Osteoprotegerin (OPG) se-
creted by stromal cells acts as a soluble neutralizing receptor
for RANKL. The balance of these two proteins aﬀects bone
mass. Therefore, we examined expression of RANKL and
OPG in tob2-deﬁcient or -overexpressing stromal cells. While
expression of OPG did not correlate clearly with expression
of Tob2 (data not shown), RANKL expression induced by
1,25(OH)2D3 and prostaglandin E2 was increased in tob2
/
stromal cells, and reduced in Tob2-overexpressing ST-2 stro-
mal cells (Fig. 4A and B). These data suggest that Tob2 is in-
volved in regulation of expression of RANKL. Because
1,25(OH)2D3-induced RANKL expression is regulated through
VDR [14], we speculated that Tob2 may functionally and/or
physically interact with VDR. To examine this possibility,
GST-tagged Tob2 and myc-tagged VDR were expressed in
COS-7 cells. Cell lysates were then subjected to GST pull-down
assay. The results revealed that Tob2 interacts with VDR
regardless of 1,25(OH)2D3 stimulation (Fig. 5).4. Discussion
Osteoclasts are multinucleated giant cells that are present
speciﬁcally in bone and that adsorb bone. Osteoclasts diﬀeren-
tiate from hematopoietic cells, and osteoblasts and/or stromal
cells are crucial for osteoclast development [15]. Bone marrow
stromal cells express an osteoclast diﬀerentiation factor called
RANKL. Treatment of hematopoietic cells with a combina-
tion of M-CSF and the soluble form of RANKL induces
osteoclast diﬀerentiation in vitro [16]. RANKL and its recep-
tor, RANK, are essential for osteoclast diﬀerentiation [17],
and targeted disruption of RANKL or RANK induces osteo-
petrosis in mice [18,19]. Overexpression of RANKL leads to
osteoporotic skeletal changes [20]. These results clearly indi-
cate that the RANKL/RANK pathway is essential for osteo-
clast development in vivo.Mock
Tob2
1 4 10 10 10
d from tob2+/+ or tob2/ bone marrow and stimulated with or without
48 h after stimulation and subjected to semi-quantitative real-time RT-
ars represent means ± SD. (B) Semi-quantitative real-time RT-PCR
or htob2F expression virus. Cells were stimulated with 0, 1, 4, 10 nM
GE2), then analyzed as in (A). ST2 stromal cell lines infected mtob2
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Fig. 5. Tob2 interacts with VDR. GST or GST-fused Tob2 was
coexpressed with 6Myc-tagged VDR in COS-7 cells and stimulated
with or without 1,25-(OH)2D3. Total protein extracts were subjected to
GST-pull-down assay followed by immunoblotting (IB) with indicated
antibodies. The bottom panel shows expression of 6Myc-tagged VDR.
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an osteoporotic phenotype, due most likely to an increased
number of osteoclasts (Figs. 2E, F and 3E). This is in contrast
with tob-deﬁcient mice, which show osteopetrotic changes be-
cause of increased proliferation and diﬀerentiation of osteo-
blasts [7]. Because expression of Tob2 was shown in both
stromal cells and osteoclasts (Fig. 3A–C), Tob2 in stromal cells
or osteoclasts might underlie the osteoporotic phenotype of
tob2-deﬁcient mice. Our data suggest that RANK expression
in osteoclast lineage cells is normal in the absence of Tob2
(Fig. 3F). In contrast, expression of RANKL by stromal cells
is increased in the absence of Tob2 (Fig. 4). The ability of stro-
mal cells to induce osteoclast diﬀerentiation is suppressed by
exogenously expressed Tob2 (Fig. 3G). Therefore, we tenta-
tively concluded that Tob2 is involved in stromal cell-mediated
osteoclast diﬀerentiation. Most likely Tob2 may negatively
regulate RANKL expression in stromal cells. The function of
Tob2 in osteoclasts remains to be clariﬁed.
Tob/BTG family proteins are involved in transcriptional reg-
ulation. For example, BTG1-associated protein Caf1/Cnot7
interacts with estrogen receptor [4] as well as RXRb [5]. We
hypothesized that Tob2 might directly or indirectly regulate
the transcription of the RANKL gene. Expression of RANKL
is regulated by 1,25(OH)2D3 and VDR as well as RXRb
[14]. Because Tob2 interacts physically with VDR (Fig. 5),
Tob2 is likely involved in VDR-mediated transcriptional regu-
lation of the RANKL gene. The precise mechanism by which
RANKL expression is mediated by Tob2 and VDR remains
unclear. Because Caf1/Cnot7 interacts with Tob2 and with
RXRb, Tob2 could be involved in regulation of the RANKL
expression through an interaction with Caf1/Cnot7 as well.
Among the Tob/BTG family proteins, Tob is very similar to
Tob2. Nevertheless, tob-deﬁcient mice and tob2-deﬁcient mice
show opposite phenotypes in terms of bone formation. Exam-
ination of bone remodeling in tob/tob2 double-knockout mice
should further our understanding of bone formation.Acknowledgements: This work was supported in parts by Grant-in-Aid
for priority area of cancer research from MEXT (Ministry of Educa-
tion, Culture, Sports, Science and Technology) Japan, research fund
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